Most Read Articles
Audrey Abella, 02 May 2018
A single administration of the fixed-dose combination consisting of netupitant plus palonosetron (NEPA) in addition to dexamethasone may be an effective strategy for preventing chemotherapy-induced nausea and vomiting (CINV) among breast cancer patients receiving combination chemotherapy consisting of anthracycline and cyclophosphamide (AC), according to results from the GIM15-NEPA* trial presented at EBCC 2018.
Rachel Soon, 01 Sep 2018

MIMS Pharmacist presents an overview of a standardized extract of Pinus pinaster bark, and its potential role in slowing down the progression of diabetic retinopathy.

Rachel Soon, 24 Apr 2018

MIMS Pharmacist presents an overview of CoQ10's physiological role, as well as contemporary research on its pharmacology and effects.

Rachel Soon, 25 Jul 2018

MIMS Pharmacist presents an overview of Lactobacillus plantarum 299v's physiological role, as well as contemporary research on its pharmacology and effects.

Serious, long-term ocular effects seen after bevacizumab treatment vs laser in eyes with ROP

14 Feb 2018

Treatment with bevacizumab for acute-phase retinopathy of prematurity (ROP), compared with laser, is associated with greater incidence of potentially serious and long-term ocular effects as shown by fluorescein angiography (FA), according to a study.

Abnormalities were seen at the periphery (avascular area, vessel leakage, shunts, abnormal vessel branching and tangles) or the posterior pole (hyperfluorescent lesions, absence of foveal avascular zone) in all 20 eyes treated with bevacizumab at 4 years of age.

On the other hand, these lesions were not present in most of the eyes that underwent laser treatment. Among the 19 laser-treated eyes, one had leakage, three had shunts and tangles, and another three had macular abnormalities.

In this single, randomized, controlled trial, the investigators compared structural outcome at age 4 years of eyes treated with intravitreal injection of bevacizumab with that of fellow eyes treated with conventional laser photoablation in type 1 ROP.

All inborn babies with type 1 zone 1 ROP (n=21; 42 eyes) at the Neonatal Intensive Care Unit of the Catholic University in Rome from 1 September 2009 to 31 March 2012 were enrolled. In 21 infants, one eye was randomly assigned to receive an intravitreal injection of 0.5 mg bevacizumab, while the fellow eye underwent conventional laser photoablation.

The investigators performed digital retinal imaging and FA at an average of 4 years following treatment in follow-up. Two experts examined fluorescein angiograms to document retinal and choroidal findings.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Audrey Abella, 02 May 2018
A single administration of the fixed-dose combination consisting of netupitant plus palonosetron (NEPA) in addition to dexamethasone may be an effective strategy for preventing chemotherapy-induced nausea and vomiting (CINV) among breast cancer patients receiving combination chemotherapy consisting of anthracycline and cyclophosphamide (AC), according to results from the GIM15-NEPA* trial presented at EBCC 2018.
Rachel Soon, 01 Sep 2018

MIMS Pharmacist presents an overview of a standardized extract of Pinus pinaster bark, and its potential role in slowing down the progression of diabetic retinopathy.

Rachel Soon, 24 Apr 2018

MIMS Pharmacist presents an overview of CoQ10's physiological role, as well as contemporary research on its pharmacology and effects.

Rachel Soon, 25 Jul 2018

MIMS Pharmacist presents an overview of Lactobacillus plantarum 299v's physiological role, as well as contemporary research on its pharmacology and effects.